RUNX2 and bone neoplasm: In terms of promoting bone tissue repair, SBGC is mainly adopted to enhance the early osteogenic differentiation of bone mesenchymal stem cells (BMSCs) in bone tumor defects through the activation of osteogenic markers ALP, runt-related transcription factor 2 (Runx2), osteopontin, osteocalcin and bone salivary protein172.